<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02358681</url>
  </required_header>
  <id_info>
    <org_study_id>AAAO1302</org_study_id>
    <nct_id>NCT02358681</nct_id>
  </id_info>
  <brief_title>Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children</brief_title>
  <official_title>Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children: A Randomized Non-inferiority Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Migraine Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ketorolac is an evidence-based, first-line acute migraine therapy that is commonly used in&#xD;
      the pediatric population; however, it is typically administered by the intravenous (IV) or&#xD;
      intramuscular (IM) routes, both of which require a painful and distressing needle stick to&#xD;
      administer.&#xD;
&#xD;
      The intranasal (IN) route is a painless and effective way of administering analgesics,&#xD;
      including ketorolac: IN ketorolac has been shown to be an effective analgesic in adults for&#xD;
      painful conditions, including acute migraine headaches. However, IN ketorolac has been&#xD;
      understudied in children, and it is not known how effective it is compared to IV ketorolac,&#xD;
      which is currently the most common way of administering ketorolac to children. If IN&#xD;
      ketorolac is shown to be no less effective than IV ketorolac, IN ketorolac may be a viable&#xD;
      and painless alternative to effectively treat acute migraine headaches in children.&#xD;
&#xD;
      Therefore, our primary aim is to demonstrate that IN ketorolac is non-inferior to IV&#xD;
      ketorolac for reducing pain in children with acute migraine headaches.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Aim: Determine whether intranasal (IN) ketorolac is non-inferior to intravenous (IV)&#xD;
      ketorolac for reducing pain in children with acute migraine headaches. We hypothesize that IN&#xD;
      ketorolac is non-inferior to IV ketorolac in reducing acute migraine headache pain by a&#xD;
      minimum clinically significant difference within 60 minutes of administration.&#xD;
&#xD;
      Secondary Aim: Determine whether there is a difference in time to achieve a clinically&#xD;
      significant reduction in pain after receiving IN ketorolac compared to IV ketorolac. We&#xD;
      hypothesize that there is no difference between IN ketorolac and IV ketorolac in the time it&#xD;
      takes to achieve a clinically significant reduction in pain.&#xD;
&#xD;
      We will conduct a prospective, double-blinded, randomized, non-inferiority, parallel 1:1&#xD;
      clinical trial of eligible children in a single urban pediatric ED. We will block randomize&#xD;
      patients to receive either 1 mg/kg IN ketorolac and an IV placebo (study group A), or 0.5&#xD;
      mg/kg IV ketorolac and an IN placebo (study group B).&#xD;
&#xD;
      We will assess the patient's pain at baseline, and then at 10 minutes, 30 minutes and 60&#xD;
      minutes after administration of the study drug. The patient will then be assessed at 2 hours&#xD;
      and 24 hours after study drug administration for outcomes related to efficacy, function, and&#xD;
      safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2015</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain score after analgesic administration (Faces Pain Scale - Revised (FPS-R)</measure>
    <time_frame>60 minutes</time_frame>
    <description>Measure the change in pain score after administration of analgesic using the Faces Pain Scale - Revised (FPS-R) at 60 minutes after analgesic administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to achieve clinically significant reduction in pain after analgesic administration (Pain score)</measure>
    <time_frame>10, 30, 60 and 120 minutes</time_frame>
    <description>Pain score will be assessed at 10, 30, 60 and 120 minutes after analgesic administration, until pain score decreases by 2/10 on the FPS-R)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 hours</time_frame>
    <description>Adverse events will be assessed at the 1- and 2-hour assessments and the 24-hour follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>ED-based outcomes (Receipt of rescue medications during emergency department visit)</measure>
    <time_frame>12 hours</time_frame>
    <description>Receipt of rescue medications during emergency department visit</description>
  </other_outcome>
  <other_outcome>
    <measure>ED-based outcomes (Headache relief in emergency department)</measure>
    <time_frame>2 hours</time_frame>
    <description>Headache relief in emergency department</description>
  </other_outcome>
  <other_outcome>
    <measure>ED-based outcomes (Headache freedom in emergency department)</measure>
    <time_frame>2 hours</time_frame>
    <description>Headache freedom in emergency department</description>
  </other_outcome>
  <other_outcome>
    <measure>ED-based outcomes (Percentage improvement in pain score between baseline and one hour)</measure>
    <time_frame>1 hour</time_frame>
    <description>Percentage improvement in pain score between baseline and one hour</description>
  </other_outcome>
  <other_outcome>
    <measure>24-hour follow up outcomes (Patient's assessment of efficacy and tolerability)</measure>
    <time_frame>24 hours</time_frame>
    <description>Patient's assessment of efficacy and tolerability</description>
  </other_outcome>
  <other_outcome>
    <measure>24-hour follow up outcomes (Sustained headache freedom)</measure>
    <time_frame>24 hours</time_frame>
    <description>Sustained headache freedom</description>
  </other_outcome>
  <other_outcome>
    <measure>24-hour follow up outcomes (Sustained headache relief)</measure>
    <time_frame>24 hours</time_frame>
    <description>Sustained headache relief</description>
  </other_outcome>
  <other_outcome>
    <measure>24-hour follow up outcomes (Use of rescue medications after discharge from the ED.)</measure>
    <time_frame>24 hours</time_frame>
    <description>Use of rescue medications after discharge from the ED.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Ketorolac, intranasal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route, single dose.&#xD;
Placebo, intravenous.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac, intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route, single dose.&#xD;
Placebo, intranasal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac, intranasal</intervention_name>
    <description>Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.</description>
    <arm_group_label>Ketorolac, intranasal</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac, intravenous</intervention_name>
    <description>Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.</description>
    <arm_group_label>Ketorolac, intravenous</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, intravenous</intervention_name>
    <description>Placebo of equal volume to IV ketorolac, to be administered by intravenous route.</description>
    <arm_group_label>Ketorolac, intranasal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, intranasal</intervention_name>
    <description>Placebo of equal volume to IN ketorolac, to be administered by intranasal route.</description>
    <arm_group_label>Ketorolac, intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Present to the emergency department with a migraine headache as defined by the&#xD;
             modified Irma criteria. The modified Irma criteria are as follows: Headache episodes&#xD;
             of 1-168 hours (7 days) presenting with at least 3 of the following 6 criteria:&#xD;
             moderate to severe episode of impaired daily activities; focal localization of&#xD;
             headache; pulsatile description; nausea or vomiting or abdominal pain; photophobia or&#xD;
             phonophobia or avoidance of light and noise; symptoms increasing with activity or&#xD;
             resolving by rest.&#xD;
&#xD;
          -  Headache severity of moderate to severe pain (i.e. at least 4/10 on the Faces Pain&#xD;
             Scale - Revised)&#xD;
&#xD;
          -  Requiring IV fluids and any IV medication (for example: ketorolac, metoclopramide,&#xD;
             prochlorperazine, ondansetron) as part of their headache treatment, as per their&#xD;
             treating attending physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to receiving ketorolac&#xD;
&#xD;
          -  Receipt of an NSAID within six hours of study drug administration&#xD;
&#xD;
          -  Presence of an intranasal obstruction that cannot be readily cleared&#xD;
&#xD;
          -  Inability to speak English or Spanish&#xD;
&#xD;
          -  Unable to complete self-report measures of pain or questionnaires&#xD;
&#xD;
          -  Critical illness&#xD;
&#xD;
          -  Frequent use of drugs for headache (i.e. regular intake of analgesics for acute&#xD;
             headaches on more than 10 days per month).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel S Tsze, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NewYork Presbyterian Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2015</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Daniel S Tsze, MD, MPH</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Intranasal</keyword>
  <keyword>Ketorolac</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Migraine</keyword>
  <keyword>Headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

